Wells Fargo & Company MN lowered its stake in Insmed, Inc. (NASDAQ:INSM) by 0.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 44,563 shares of the biopharmaceutical company’s stock after selling 331 shares during the period. Wells Fargo & Company MN owned 0.07% of Insmed worth $765,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INSM. Parametric Portfolio Associates LLC increased its position in shares of Insmed by 39.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 4,063 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Insmed by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 3,781,483 shares of the biopharmaceutical company’s stock worth $66,214,000 after purchasing an additional 173,532 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Insmed by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 493,181 shares of the biopharmaceutical company’s stock worth $8,635,000 after purchasing an additional 22,345 shares during the last quarter. Morgan Stanley increased its position in shares of Insmed by 2.7% in the 1st quarter. Morgan Stanley now owns 545,514 shares of the biopharmaceutical company’s stock worth $9,552,000 after purchasing an additional 14,412 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Insmed by 6.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 283,167 shares of the biopharmaceutical company’s stock worth $4,959,000 after purchasing an additional 18,331 shares during the last quarter. 72.78% of the stock is owned by institutional investors.

In other news, Director Melvin Md Sharoky sold 50,000 shares of Insmed stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total value of $1,368,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald J. Hayden, Jr. sold 45,000 shares of Insmed stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the completion of the transaction, the director now directly owns 71,131 shares of the company’s stock, valued at $2,110,456.77. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Insmed, Inc. (NASDAQ INSM) opened at $30.15 on Wednesday. Insmed, Inc. has a fifty-two week low of $11.19 and a fifty-two week high of $31.84. The company has a debt-to-equity ratio of 0.13, a quick ratio of 15.21 and a current ratio of 15.21.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/08/insmed-inc-insm-shares-sold-by-wells-fargo-company-mn.html.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Tuesday. Cowen and Company reissued a “buy” rating and issued a $54.00 target price on shares of Insmed in a research report on Friday, November 3rd. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Insmed in a research report on Monday. ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, Robert W. Baird reissued a “positive” rating and issued a $32.00 target price (up previously from $23.00) on shares of Insmed in a research report on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Stock Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related stocks with our FREE daily email newsletter.